

Curriculum Vitae



Vivian Gudrun Oehler, M.D.

09/23/2020

1. Personal Data:

Place of Birth: New York City, NY

2. Education:

1985-1989 Harvard University, B.A. Government, 1989
1990-1992 S.U.N.Y. Stony Brook, Post-baccalaureate premed courses
1993-1997 Case Western Reserve University School of Medicine, M.D., 1997

3. Postgraduate Training:

1997-1998 Intern, Department of Medicine, University of Washington
1998-2000 Resident, Department of Medicine, University of Washington
2000- 2004 Fellow, Division of Hematology, Department of Medicine, University of Washington
2002- 2004 Post-Doctoral Research Fellow, Jerald Radich Laboratory, Fred Hutchinson Cancer Research Center

4. Faculty Positions Held:

2004-2005 Research Associate, Fred Hutchinson Cancer Research Center
2005- 11/2008 Associate in Clinical Research, Fred Hutchinson Cancer Research Center
2004- 2008 Acting Instructor, Division of Hematology, Department of Medicine, University of Washington
2008-11/2008 Acting Assistant Professor, Division of Hematology, Department of Medicine, University of Washington
12/2008-2014 Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
12/2008-2014 Assistant Professor, Division of Hematology, Department of Medicine, University of Washington
2014- present Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
2014-present Associate Professor, Division of Hematology, Department of Medicine, University of Washington

5. Hospital Positions Held:

2004- present Attending physician, Hematology, University of Washington Affiliated Hospitals

6. Honors:

1996- present Alpha Omega Alpha
2004-2006 American Society of Hematology, Fellow Award
2007-2009 V Foundation for Cancer Research, V Foundation Scholar
2012 Philip and Helen Fialkow Scholar Award, University of Washington, Department of Medicine

7. Board Certification:

2004- present Diplomat, American Board of Internal Medicine, Oncology
2003- present Board eligible, Hematology

8. Licensure:

1999- present State of Washington Medical License MD00037702

9. Professional Organizations:

2003-present Member, American Society of Hematology

2007-present Member, Southwest Oncology Group

2017-ongoing Member, Children's Oncology Group

10. Teaching Responsibilities:

2004 – present Attending physician Seattle Cancer Care Alliance, seeing patients with CML, MPNs, and AML.

2009 – present Attending physician on Leukemia service

2003 -- present University of Washington Medical School Blood and Cancer Small Group Facilitator

Post-Doctoral Fellows in the Laboratory

2008 - 2009 Taimei Yang, PhD

2009 – 2016 Valerie Morris, PhD

2014 – 2015 Maya Hughes, MD

2017-2018 Ken Lindsay, PhD

Undergraduate Students

Summer 2012 Sean Boaglio, Fred Hutch Summer Student Intern Program

2013-2014 Brendan Korb, Undergraduate Research Program UW

Recent invited talks:

- a) Fred Hutchinson Cancer Research Center Grand Rounds. MicroRNAs in AML: biomarkers and mechanisms. Seattle, WA, June 12, 2017.
- b) Hematology-Oncology Fellows Lecture Series. Chronic myeloid leukemia 2014, 2016, 2018, 2019
- c) UW/SCCA Annual Comprehensive Hematology & Oncology Review Course. Chronic Myeloid Leukemia: a guide to the guidelines. CME-sponsored Board Review Course. Seattle, WA, September 2016, 2017, 2018, 2019.
- d) *OncLive*, State of the Science Summit. Classical Myeloproliferative Neoplasms: diagnosis, risk prognostication, and therapeutic strategies. Seattle, WA, September 19, 2018.
- e) Fred Hutchinson Cancer Research Center Grand Rounds. Chronic Myeloid Leukemia 2018: a guide to the guidelines. Seattle, WA, September 24, 2018.
- f) XIIIth Post-ASH CML+MPN workshop Program. Characterizing MPN neoantigens and T cell responses for therapeutic applications. San Diego, CA, December 4-5, 2018.
- g) *OncLive*, State of the Science Summit. Optimizing quality of life and molecular response in CML: TKI cessation and dose reduction. Seattle, WA, June 5, 2019.
- h) *OncLive*, State of the Science Summit. Classical Myeloproliferative Neoplasms: risk prognostication and therapeutic strategies. Seattle, WA, June 5, 2019
- i) Leukemia and Lymphoma Society, Northern CA Blood Cancer Conference (BCC). Chronic Myeloid Leukemia in 2020: ASH, ASCO and beyond. San Francisco, CA, January 25, 2020
- j) ASCO *Advantage* Program. Treatment Decisions for Advanced Stage CML (Resistance & Progression) and CML Care Delivery. Alexandria, VA.
- k) American Society of Hematology Education Session. Chair and Speaker. First Generation vs. Second Generation TKI - Which is Best At Diagnosis of Chronic Phase Chronic Myeloid Leukemia? December 2020.

11. Editorial Responsibilities:

12. Special National Responsibilities:

October 2010	Ad hoc reviewer, NIH Molecular and Cellular Hematology Study Section
November 2012	Reviewer, Peer Reviewed Cancer Research Program, DOD
2013- 2017	ASH Scientific Committee Member, Myeloid Neoplasia
December 2013	Speaker, American Society of Hematology CML Education Session
April 2016	Reviewer, NIH Special Emphasis Panel/Scientific Review Group
2017 – ongoing	Reviewer, American Society of Hematology Fellow and Junior Faculty Scholar Awards, Research Training Award for Fellows (RTAF) and HONORS (Hematology Opportunities for the Next Generation of Research Scientists) Awards 2017, 2018, 2019, and 2020
2018 - 2020	NCCN Myeloproliferative Neoplasms Panel, committee member and writing member v1.2020 Myeloid-Lymphoid Neoplasms with Eosinophilia.
2019 - ongoing	NCCN Chronic Myeloid Leukemia Panel, committee member
2019	Author, Chronic Myeloid Leukemia, American Society of Hematology Self-Assessment Program (ASH-SAP, 7 th edition).
2019 - ongoing	ASH Publications Committee, appointed to a 4-year term
2020 - ongoing	ASCO Advantage Course: Chronic Myeloid Leukemia – content developer and speaker.
2020	Chair, American Society of Hematology CML Education Session

13. Special Local Responsibilities

2011 – present	University of Washington Division of Hematology Grand Rounds. Direct CME accredited Hematology Grand Rounds given on the 1 st , 3 rd , and 5 th Friday of each month; select speakers and coordinate program.
2015 – present	Scientific Review Committee B, Fred Hutch, chair, reviews research studies for scientific merit and integration of the research effort with regards to competing protocols and Cancer Consortium research priorities.

14. Research Funding:

Active:

Hyundai Hope on Wheels (P.I. Oehler, V.G.) 1/1/2020-12/31/2021
2019 Scholar Hope Grant. Optimizing risk stratification and targeting therapy resistance in pediatric acute myeloid leukemia patients using microRNA-based approaches

Alex’s Lemonade Stand (P.I. Oehler, V.G. and Meshinchi, S.) 10/1/2017 – 3/30/2021
2017 Innovation Award. Establishing the function of novel microRNAs associated with resistance and relapse in pediatric AML. Aim 1 examines how downstream targets of newly discovered novel miRNAs contribute to leukemia. Aim 2 establishes if novel miRNA expression is associated with outcomes.

Pfizer (P.I.: Oehler, V.G.) 7/1/2016 – 10/15/2021
 ASPIRE Chronic Myelogenous Leukemia Awards Program
 Mechanisms contributing to response and tolerance of bosutinib in chronic myeloid leukemia patients. This investigator-initiated study examines mechanisms of resistance to TKI therapy and other therapies in the treatment of CML using high-throughput drug screening and RNA-seq.

Fred Hutch COVID-19 Pilot Award (P.I.: Oehler, V.G. and Schiffer, J.T.) 6/1/2020-5/31/2021
 Repurposing cancer therapeutics for treatment of SARS-CoV-2 infection.

In collaboration with Michael Gale PhD we will perform in vitro high-throughput screening (HTS) of 96 drugs that are FDA approved or in clinical trial for various cancers against a battery of COVID-19 infected cell lines. Clinical testing will then be predicated on selecting the most potent agents (effective at nanomolar concentrations and predicted to have rapid suppressive activity with Dr. Schiffer's existing SARS-CoV-2 mathematical model.

R01 CA 184798-01A1 (P.I. Atallah, E., Co-Investigator, Oehler, V.G.) 9/1/2014 - 08/31/2020
Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs). The specific aims of this project are: 1) To characterize the clinical characteristics associated with CML recurrence after TK1 discontinuation, 2) To describe health status changes for patients who discontinue (and restart) TKIs, and 3) To explore how patients will make the decision to discontinue TKIs.

Pfizer (P.I.: Oehler, V.G.) 6/12/2015 – 5/31/2020
A Phase 4 Safety and Efficacy Study of Bosutinib in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors. This is a clinical trial.

Novartis (P.I.: Oehler, V.G.) 04/10/2018 – 03/31/2020
A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors. This is a clinical trial.

Bristol Myers Squibb (P.I.: Oehler, V.G.) 9/29/2017 – 12/31/2022
Determining change in cardiovascular and metabolic risks in patients with chronic phase CML receiving BCR-ABL tyrosine kinase inhibitor first-line therapy. This is a clinical trial

Amphivena Therapeutics (P.I.: Oehler, V.G.) 02/01/2018 – 12/31/2020
A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia. This is a clinical trial.

Cure CML Consortium (P.I.: Oehler, V.G.)
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease. This is a clinical trial.

Ascentage (P.I.: Oehler, V.G.)
A phase 1B study of the pharmacokinetics, safety, and efficacy of orally administered HQP1351 in subjects with refractory chronic myeloid leukemia. This is a clinical trial.

Actuate/Courante Oncology (P.I.: Oehler, V.G.)
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3 β) Inhibitor, as a Single Agent or Combined with Ruxolitinib, in Patients with Myelofibrosis. This is a clinical trial.

Cepheid (P.I.: Oehler, V.G.)
Specimen Collection for Analytical, Pre-Clinical and Clinical Studies for the Xpert BCR-ABL Ultra p190 Test (Prospective SOC Specimens).

Astex Pharmaceuticals, Inc. (P.I.: Oehler, V.G.)
Phase 1 Study of Safety, Pharmacokinetics, and Preliminary Activity of TAS1440, as a Single Agent and in Combination with All-Trans Retinoic Acid (ATRA) in Subjects with Relapsed or Refractory (r/r) Acute Myeloid Leukemia

Past:

MPN Research Foundation (P.I. Oehler, V.G. and Bleakley, M) 10/1/2017 – 9/30/2019
 2017 Challenge Grant. Characterizing T-cell Neoantigens and T-cell Responses to Myeloproliferative Neoplasm-associated Mutations.

American Society of Hematology (P.I.: Oehler, V.G.) 6/15/2017 – 06/14/2018
 ASH Bridge Fund Award. Using microRNAs to improve risk-stratification for pediatric AML.

FHCRC /OBLITERIDE (P.I.: Oehler, V.G.) 6/1/2014 - 05/31/2016
 Developing microRNAs as a therapeutic strategy in acute myeloid leukemia
 The goal of this pilot project is to establish optimal miRNA and naocarrier formulation and antibody targeting for targeted delivery using pH-responsive nanocarriers.

SWOG Development Award (P.I.: Oehler, V.G.) 1/1/2013-12/31/2014
 The Hope Foundation
 Aberrant myeloid differentiation and microRNA regulation in acute leukemia

R01 CA140371 (P.I.: Oehler, V.G.) 7/1/2009 - 6/30/2014
 NIH/NCI
 Integrating Diagnostics with Therapeutic Strategies in Chronic Myeloid Leukemia

FHCRC/UW Cancer Consortium (P.I.: Oehler, V.G.) 6/15/2013 – 6/14/2014
 NCI/Pilot Funds
 The genomics of primary myelofibrosis and its impact on megakaryocytes and fibrosis

2UL1TR000423 (P.I.: Oehler, V.G.) 6/1/2012- 8/31/2013
 Institute of Translational Health Sciences
 Elucidating microRNAs in myeloid differentiation in leukemia

FDN ASH NA (P.I.: Oehler, V.G.) 7/1/2009 - 6/30/2013
 American Society of Hematology
 Progression and resistance in chronic myeloid leukemia

FDN LSDF (P.I.: Cheever, M) 8 /4/2010 – 10/31/2012
 Life Sciences Discovery Fund
 Fred Hutchinson/University of Washington Cancer Consortium Phase I Clinical Trials Program (initial pilot).

SUB R01 GM084163-01A1 (P.I.: Yeung, K.Y.) 9/30/2009 - 2/09/2012
 NIGMS
 Prediction and Network Construction Using High-Throughput Data

FDN LLS 6160-08 (P.I.: Oehler, V.G.) 10/1/2007 - 9/30/2011
 LEUK & LYMPH
 Expression, function, and regulation of genes associated with chronic myeloid leukemia progression and imatinib mesylate resistance

K23 CA106796 (P.I. Oehler, V.G.) 7/1/2004-7/31/2009
 NIH/NCI
 Examination of imatinib mesylate resistance in CML

FDN V Foundation (P.I.: Oehler, V.G.) 11/1/2007 - 10/31/2009

V Foundation Scholar

The identification of prognostic factors in CML progression and imatinib mesylate resistance.

FDN ASH

(P.I. Vivian G. Oehler)

7/1/2004-6/30/2006

Clinical/Translational Research Scholar Award

Bibliography:**a) Publications in refereed journals:**

1. **Oehler VG**, Radich JP. Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia. *Curr Oncol Rep.* **2003**; 5(5): 426-35. PMID 12895396.
2. **Oehler VG**, Radich JP, Storer B, Blume KG, Chauncey T, et al. Randomized trial of allogeneic – related bone marrow transplantation vs. peripheral blood stem cell transplantation for chronic myeloid leukemia. *Biol Blood Marrow Tr.* **2005**; 11(2): 85-92. PMID 15682068.
3. **Oehler VG**, Radich JP. Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction. *Current hematologic malignancy reports.* **2006**; 1(3):152-9.
4. Radich JP, Dai H, Mao M, **Oehler V**, Schelter J, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. *Proc Natl Acad Sci USA.* **2006**; 103(8): 2794-2799. PMID 16477019.
5. Bonig H, Priestley GV, **Oehler V**, and Papayannopoulou T. Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC. *Exp Hematol.* **2007**; 35(2): 326-334. PMID 17258081.
6. **Oehler VG**, Gooley T, Snyder DS, Johnston L, Lin A, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. *Blood.* **2007**; 109(4): 1782-1789. PMID 17062727.
7. **Oehler V**, Radich JP. Monitoring of patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy. *Clin Lymphoma Myeloma.* **2007**; Suppl 2: S58-63. PMID 17382014.
8. **Oehler V** and Radich JP. Monitoring chronic myeloid leukemia in the age of tyrosine kinase inhibitors. *JNCCN.* **2007**; 5(5): 497-504. PMID 17509253.
9. **Oehler VG**, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, et al. Absolute quantitative detection of ABL tyrosine kinase domain point mutations using a novel nanofluidic platform and mutation-specific PCR. *Leukemia.* **2009**; 23(2): 396-399. PMID 18615105.
10. **Oehler VG**, Guthrie K, Cummings CL, Sabo K, Wood BL, et al. Preferentially Expressed Antigen in Melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. *Blood.* **2009**;114(15): 3299-3308. PMID 19625708.
11. **Oehler VG***, Yeung KY*, Choi YE, Bumgarner RE, Raftery AE, et al. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. *Blood.* **2009**; 114(15): 3292-3298. PMID 19654405. ***Shared first author**
12. Ho PA, Alonzo TA, Kopecky KJ, Miller KL, Kuhn J, Zeng R, Gerbing RB, Raimondi SC, Hirsch BA, **Oehler V** et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. *Leukemia.* **2010**; 24(5): 909-913. PMID 20376086.
13. Ito H, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento W, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, **Oehler VG**, Radich J, Jordan CT, and Reya T. Regulation of myeloid leukemia by the cell fate determinant Musashi. *Nature.* **2010**; 466(7307): 765-768. PMID 20639863.
14. Kim YM, Ma H, **Oehler VG**, Gang EJ, Nguyen C, et al. The gamma catenin/CBP complex maintains survivin transcription in β -catenin deficient/depleted cancer cells. *Curr Cancer Drug Targets.* **2011**; 11(2): 213-225. PMID 21158719.
15. Champagne MA, Fu CH, Chang M, Chen H, Gerbing RB, Alonzo TA, Cooley LD, Heerma NA, **Oehler V**, et al. Higher dose imatinib for children with de novo chronic phase myelogenous

- leukemia: a report from the Children's Oncology Group. *Pediatr Blood Cancer*. **2011**; 57(1): 56-62. PMID 21465636.
16. Ho P, Kopecky K, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi S, Hirsch B, **Oehler V**, Hurwitz CA et al. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children's Oncology Group and SWOG. *Blood*. **2011**; 118(17): 4561-4566.
 17. Yeung KY, Gooley TA, Zhang A, Raftery AE, Radich JP, and **Oehler VG**. Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data. *Bioinformatics*. **2012**; 28(6): 823-830.
 18. Pogossova-Agadjanyan E, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, **Oehler VG**, Petersdorf S, Radich JP, Willman CL, Meshinchi S, and Stirewalt DL. The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia. **2013**; *PLOS One*, 8(8): e70812.
 19. Cortes JE, Kim DW, Pinella-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *New Engl J Med*. **2013**; 369(19): 1783-1796 (PACE Investigator).
 20. Morris VA, Zhang A, Yang T, Stirewalt DL, Ramamurthy R, Meshinchi S, and **Oehler VG**. MicroRNA-150 expression induces myeloid differentiation of human acute leukemia cells. **2013**; *PLOS One*, 8(9): e75815.
 21. Zimdahl B, Ito T, Blevins A, Bajaj J, Konuma T, Weeks J, Koechlein CS, Kwon HY, Arami O, Rizzieri D, Broome HE, Chuah C, **Oehler VG**, Sasik R, Hardiman G, and Reya T. Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. *Nat Genet*. **2014**; 46(3): 245-252.
 22. Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum F, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett AK, List AF, Fang M, **Oehler V**, Petersdorf SH, Pogossova-Agadjanyan E, Radich J, Willman CW, Meshinchi S, and Stirewalt D. Prognostic significance of NPM1 mutations in the absence of FLT3-ITD in older patients with AML: a SWOG and MRC/NCRI report. *J Clin Oncol*. **2015**; 33(10):1157-64.
 23. Becker P, Huang J, Basu S, Zhao X, Chien S, Fang M, **Oehler V**, and Appelbaum F. Mesenchymal Stromal Cells Derived from Acute Myeloid Leukemia Bone Marrow Exhibit Aberrant Cytogenetics and Cytokine Elaboration. *Blood Cancer J*. **2015**; 10(5): e301.
 24. Kwon HY, Bajaj J, Ito T, Blevins A, Konuma T, Weeks J, Lytle NK, Koechlein CS, Rizzieri D, Chuah C, **Oehler VG**, Sasik R, Hardiman G, and Reya T. Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. *Cell Stem Cell*. **2015**; 17(2): 152-164.
 25. Martinelli G, **Oehler VG**, Papayannidis C, Courtney R, Shaik, NM, Zhang X, et al. Treatment with PF-04449913, an oral smoothed antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. *Lancet Haematology*. *Lancet Haematol*. **2015**; 2(8):e339-46.
 26. *Morris VA, Cummings C, Korb B, Boaglio SM, and **Oehler VG**. Deregulated KLF4 expression in myeloid leukemias alters cell proliferation and differentiation through microRNA and gene targets. *Mol Cell Biol*. **2015** ; 36(4): 559. PMID: PMC4751692.
 27. Soma L, **Oehler VG**, Ding C, and Cherian S. Small, abnormal B lymphoid blast populations in Chronic Myelogenous Leukemia at diagnosis: Does this finding indicate an accelerated course? *Cytometry B Clin Cytom*. **2016**; 90(5):440-8.
 28. Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, Le Coutre P, Clark R, Stenke L, Andorsky D, **Oehler V**, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes T, Kantarjian HM, Shah NP, Talpaz M, Deininger MW for the EPIC Investigators. Ponatinib Versus Imatinib in Newly Diagnosed Chronic Myeloid Leukemia: an International, Randomized, Open-Label, Phase 3 Trial. *Lancet Oncology*. **2016**; 17(5): 612-621.
 29. Brehme M, Koschmieder S, Montazeri M, Copland M, **Oehler VG**, Radich JP, Brummendorf TH, and Schuppert A. Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia. *Sci Rep*. 2016 Apr 6;6:24057. doi: 10.1038/srep24057.

30. Noren DP, Long BL, Norel R, Rrhissorrakrai K, Hess K, Hu CW, et al. A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. *PLOS Comput Biol.* **2016**; 12(6):e1004890. PMID: PMC4924788.
31. Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, **Oehler VG**, Alonzo TA, and Meshinchi S. miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group. *Pediatr Blood Cancer.* **2016**; 63(12): 2096-2103.
32. Son HN, Srinivasan S, Yhee JY, Das D, Daugherty BK, Berguig GY, **Oehler VG** (error *-name spelled Oehle*), Kim SH, Kim K, Kwon IC, Stayton PS, and Convertine AJ. Chemotherapeutic copolymers prepared via the RAFT polymerization of prodrug monomers. *Polymer chemistry.* **2016**; 7 (27): 4494-4505.
33. Bajaj J, Konuma T, Lytle NK, Kwon HY, Ablack JN, Cantor JM, Rizzieri D, Chuah C, **Oehler VG**, Broome EH, Ball ED, van der Horst EH, Ginsberg MH, and Reya, T. CD98-mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia. *Cancer Cell.* **2016** Nov 14;30(5):792-805.
34. Lee SI, Celik S, Logsdon B, Lundberg SM, Martins TJ, Oehler VG, Estey EH, Miller CP, Chien S, Dai J, Saxena A, Blau CA, and Becker PS. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. *Nat Commun.* **2018** Jan 3;9(1):42.
35. Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, **Oehler VG**, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. *BMC Cancer.* **2018** Apr 2;18(1):359.
36. *Savona MR, Pollyea DA, Stock W, **Oehler VG**, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE. Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. *Clin Cancer Res.* **2018** May 15;24(10):2294-2303.
37. Cortes JE, Smith BD, Wang ES, Merchant A, **Oehler VG**, Arellano M, DeAngelo DJ, Pollyea, DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Shaik MN, Laird AD, O'Connell A, Chan G, Schroeder MA. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results. *Am J Hematol.* **2018** Nov; 93(11): 1301-1310.
38. Gotlib J, Gerds AT, Bose P, et al. Systemic Mastocytosis, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* **2018** Dec;16(12):1500-1537.
39. Hoang VT, Verma D, Godvarthy PS, Llvona P, Steiner M, Gerlach K, Michels BE, Bohnenberger H, Wachter A, Oellerich T, Muller-Kuller U, Weissenberger E, Voutsinas JM, **Oehler VG**, Farin HF, Zornig M, Krause DS. The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia. *Leukemia.* **2019** Jan 11. doi: 10.1038/s41375-018-0358-8.
40. Godavarthy S, Herkt S, Weissenberger E, Aggoune D, Pan KT, Voutsinas JM, Wu Q, Muller MC, Oellerich T, **Oehler VG**, Van Etten RA, Lausen J, and Krause DS. The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis. *Haematologica.* **2019** Apr 24. pii: haematol.2018.212365. doi: 10.3324/haematol.2018.212365.
41. Houck K, Yuan H, Tian Y, Cramer D, Zhou A, Liu K, Zhou Z, Wu X, Zhang J, **Oehler VG**, and Dong JF. Physical Proximity and Functional Cooperation of Glycoprotein 130 and Glycoprotein VI in Platelet Membrane Lipid Rafts. *J Thromb Haemost.* **2019** Sep;17(9):1500-1510.
42. Halpern AB, Howard NP, Othus M, Hendrie PC, Baclig NV, Buckley SA, Percival MM, Becker PS, Scott BL, **Oehler VG**, Gernsheimer TB, Keel SB, Orozco JJ, Cassaday RD, Shustov AR, Hartley GA, Welch VL, Estey EH, Walter RB. *Leukemia.* **2020** Feb;34(2):635-639.
43. Smith J, Ries R, Hylkema T, Alonzo T, Gerbing R..... **Oehler V**, Bolouri H and Meshinchi S. Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-positive AML Defines Novel Therapeutic Options – COG and TARGET Pediatric AML Study. *Clinical Cancer Research.* **2020**, Feb 1;26(3):726-737.

44. Hochhaus A, Gambacorti-Passerini C, Abboud C et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. *Leukemia*. **2020** Aug;34(8):2125-2137. PMID: PMC7387243.
45. Palmieri R, Buckley SA, Othus M, Halpern AB, Percival MM, Scott, BL, Hendrie PC, Becker PS, **Oehler VG**, Estey EH, Walter RB. Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm. *Leuk Lymphoma*. **2020** Jul;61(7):1728-1731. PMID: PMC7384960.
46. Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. *Leukemia*. **2020** Aug;34(8):2125-2137. PMID: PMC7387243.
47. Gerds AT, Gotlib J, Deininger MW, Dunbar A, Elshoury A, George TI, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall AT, McMahon B, Mohan SR, **Oehler V**, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder DS, Stein BL, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward DC, Bergman MA, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. **2020** Sep;18(9):1248-1269.
48. Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore JO, Naqvi K, **Oehler V**, Pallera AM, Patnaik M, Pratz K, Pusic I, Rose MG, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *Natl Compr Canc Netw*. **2020** Oct 1;18(10):1385-1415.
49. Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, **Oehler VG**, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. *JAMA Oncol*. **2020** Nov 12:e205774. doi: 10.1001/jamaoncol.2020.5774.
50. Sari IN, Yang YG, Wijaya YT, Jun N, Lee S, Kim KS, Bajaj J, **Oehler VG**, Kim SH, Choi SY, Park SH, Kim DW, Reya T, Han J, Kwon HY. AMD1 is required for the maintenance of leukemic stem cells and promotes chronic myeloid leukemic growth. *Oncogene*. **2020** Nov 17. doi: 10.1038/s41388-020-01547-x.

b) Book chapters:

1. Coveler A and **Oehler VG**. Chronic myeloid leukemia. In: Estey EE and Appelbaum FA, eds. *Leukemia and Related Disorders: Integrated Treatment Approaches*. New York, NY: Humana Press (Springer Science + Business Media); 2012.
2. **Oehler, VG**. Update on Current Monitoring Recommendations in Chronic Myeloid Leukemia: Practical Points for Clinical Practice. American Society of Hematology Education Program 2013, Hematology 2013.
3. Sweet K and **Oehler VG**. Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: When is this a Safe Option to Consider? American Society of Hematology Education Program 2013, Hematology 2013.
4. **Oehler VG** and Apperley J. Chronic myeloid leukemia. American Society of Hematology Self-Assessment Program (ASH-SAP, 7th edition) **2019**.
5. **Oehler VG**. First Generation vs. Second Generation TKI - Which is Best At Diagnosis of Chronic Phase Chronic Myeloid Leukemia? Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):228-236.

16. Other:

Reviewer duties:

Journal articles:

Journal of Clinical Investigation, Blood Advances, Blood, JAMA, Molecular and Cellular Biology, PLOS One, Leukemia, Haematologica.

Abstract reviewer and session moderator:

American Society of Hematology 2009 Oncogenes and Tumor Suppressors oral abstract session

American Society of Hematology 2011 Chronic Myeloid Leukemia Biology and Pathophysiology excluding Therapy oral abstract session

American Society of Hematology 2013 Chronic Myeloid Leukemia Biology and Pathophysiology excluding Therapy invited oral abstract reviewer

American Society of Hematology 2014 Chronic Myeloid Leukemia Biology and Pathophysiology excluding Therapy coordinating oral abstract reviewer